The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia

The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia

Since their introduction, tyrosine kinase inhibitors (TKIs) have radically changed the treatment paradigm of Chronic Myeloid Leukemia (CML), leading to deep and lasting molecular responses and profoundly influencing survival. However, cancer-therapy-related Cardiovascular Toxicities (CTR-CVTs) assoc...

Full description

Bibliographic Details
Main Authors:	Alessandro Costa, Raimondo Pittorru, Giovanni Caocci, Federico Migliore, Francesco Tona, Olga Mulas, Giorgio La Nasa
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Hemato
Subjects:	TKI cardiovascular toxicity CML
Online Access:	https://www.mdpi.com/2673-6357/4/3/17

Similar Items

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
by: Kamal Chamoun, et al.
Published: (2019-01-01)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu, et al.
Published: (2020-02-01)

Atypical presentation of chronic myeloid leukemia with visual disturbance
by: Rachana Chennamaneni, et al.
Published: (2018-01-01)

Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment
by: Lukas Häselbarth, et al.
Published: (2023-11-01)

Mutation resistant to tyrosine kinase inhibitors in chronic myeloid leukemia : about a case
by: Ibtissem KIHEL, et al.
Published: (2020-06-01)

Mutation resistant to tyrosine kinase inhibitors in chronic myeloid leukemia : about a case
by: Ibtissem KIHEL, et al.
Published: (2020-06-01)

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience
by: Beatriz Felicio Ribeiro, et al.
Published: (2015-08-01)

Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials
by: Fateen Ata, et al.
Published: (2023-12-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
by: Raquel Alves, et al.
Published: (2021-09-01)

Update in Childhood Chronic Myeloid Leukemia
by: Fiorina Giona, et al.
Published: (2022-11-01)

Male Fertility and Fatherhood in Chronic Myeloid Leukemia: Current Understanding and Future Perspectives
by: Ahmed Adel Elsabagh, et al.
Published: (2024-02-01)

Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia
by: Huda F Ebian, et al.
Published: (2022-01-01)

Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment
by: Ruth Stuckey, et al.
Published: (2023-06-01)

SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection
by: Elisabetta Abruzzese, et al.
Published: (2020-04-01)

Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model
by: Shan Cheng, et al.
Published: (2021-10-01)

Allogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors
by: Ahmet Emre Eskazan, et al.
Published: (2018-08-01)

Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
by: Olga Mulas, et al.
Published: (2021-09-01)

An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States
by: Vivek Kumar, et al.
Published: (2018-02-01)

Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia
by: Christian Boni, et al.
Published: (2021-05-01)

Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis
by: Raquel Alves, et al.
Published: (2022-08-01)

Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells
by: Wioleta Dudka, et al.
Published: (2022-12-01)

The effectiveness of tyrosine kinase inhibitor for chronic myeloid leukemia in tuberous sclerosis. A case report and review of literature
by: Abdulrahman Al‐Abdulmalek, et al.
Published: (2023-03-01)

Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy
by: Massimo Breccia, et al.
Published: (2022-06-01)

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
by: Alberto Blanco Sánchez, et al.
Published: (2023-07-01)

Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors
by: Hyeok-Jae Jang, et al.
Published: (2021-11-01)

Debating Frontline Therapy in Chronic Myeloid Leukemia
by: Xia Bi, et al.
Published: (2021-09-01)

Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
by: Paulo Rodrigues-Santos, et al.
Published: (2018-11-01)

NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
by: Gianfranco Catalano, et al.
Published: (2020-10-01)

Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2
by: Sara Galimberti, et al.
Published: (2020-09-01)

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
by: Oliver Herrmann, et al.
Published: (2019-07-01)

Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia
by: Paulina Kwaśnik, et al.
Published: (2021-07-01)

Are Successful Pregnancies an Achievable Goal in Patients with Chronic Myeloid Leukaemia?
by: Zhanet Grudeva-Popova, et al.
Published: (2019-08-01)

Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment
by: Yi-gang Guo, et al.
Published: (2024-12-01)

Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response
by: Shifang Wang, et al.
Published: (2020-07-01)

Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption
by: Judit Demeter, et al.
Published: (2021-02-01)

The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia
by: María Nieves Saez Perdomo, et al.
Published: (2024-03-01)

Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors
by: Giovanni Caocci, et al.
Published: (2020-04-01)

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
by: Elena Karg, et al.
Published: (2022-12-01)

Evaluation of Imatinib adherence in chronic myeloid leukemia patients in Babylon Province, Iraq
by: Athmar Kadhim Gatea, et al.
Published: (2023-01-01)